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Denis O’Sullivan, Oliver FitzGerald, Philip S. Helliwell 
 
ABSTRACT: Background. Improving the assessment of psoriatic arthritis (PsA) is a 
key purpose of the Group for Research and Assessment of Psoriasis and PsA 
(GRAPPA). Herein, we report the proceedings of the GRAPPA composites workshop 
at the 2019 GRAPPA annual meeting and the membership’s recommended next 
steps. 
Methods. A review of continuous composite measures was conducted in an 
introductory workshop, followed by 10 breakout group sessions and a final plenary 
session for feedback and voting. 
Results. Participants included 154 members: 87 rheumatologists, 18 dermatologists, 
2 rheumatologist/dermatologists, 12 patient research partners (PRPs), 14 
academics, 1 methodologist, and 20 industry members. Of voting members, 88.8% 
agreed a need exists for a continuous composite measure for routine practice, but 
only 62% were currently using a composite measure and, of these, 27% were using 
the Disease Activity Score (DAS) 28, which is not a PsA-specific measure; 20% were 
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using a PsA-specific measure such as PsA DAS (PASDAS), Composite Psoriatic 
Disease Activity Index (CPDAI), or Disease Activity Index for PsA (DAPSA). 
Members felt the existing measures were not feasible in their current 
forms (CPDAI (84%), PASDAS (82%), and DAPSA (47%)) and that 
modification should be tested. The majority (76%) agreed that disease impact 
should be measured separately from disease activity.  
Conclusion. The GRAPPA membership supports the need for a continuous 
composite measure of disease activity for use in routine clinical care, the separate 
measurement of disease impact and activity, and the testing of modifications to 
candidate instruments rather than the development of new measures.  
Key Indexing Terms: Psoriatic Arthritis, Outcome Measurement, Composite 
Measures, GRAPPA 
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Background 
Improving the assessment of psoriatic arthritis (PsA) is one of the key purposes of 
the Group for Research and Assessment of Psoriasis and PsA (GRAPPA) and was 
identified as a priority at the 2016 GRAPPA leadership retreat.(1) The development 
of continuous, as distinct from categorical, composite measures of disease activity 
that are specific to PsA has been an area of research focus. A number of different 
continuous composite measurtes have been developed for use in Rheumatoid 
Arthritis (RA) such as the Clinical Disease ACtviity Index (CDAI), Simplified Disease 
ACtcvitiy Index (SDAI) and Disease Activity Score 28 (DAS 28). It is recognised that 
considerable advances have been made in the care of patients with RA with the 
development and widespread adoption of a single outcome measure.The DAS28 is 
an instrument with well-recognised, clinically recognisable thresholds of remission, 
as well as low, moderate, and high disease activity. A continuous measure, such as 
the DAS28, allows the practising clinician and patient to assess grades of response 
and to readily track change over time. By comparing data from different trials, 
cohorts and registries become much more accessible for clinicians and payers with 
the DAS28 as a universally recognised metric. This facilitates the adoption of new 
research findings, such as treat-to-target, into routine practice. Although the DAS28 
has been shown to be discriminative and responsive in PsA,(2) it has been 
psychometrically surpassed in that disease by more PsA-specific measures 
reviewed below. 
A number of composite measures of disease activity have been developed for 
PsA, but it has been challenging to achieve consensus on which instrument to take 
forward.(3, 4) The following questions were asked at the 2019 GRAPPA composites 
workshop: 
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1. Is there a need for a continuous composite measure?  
2. What are the barriers to wider adoption of existing measures?  
3. How does the PsA Impact of Disease (PsAID) influence the use  
   of composite activity measures in PsA?  
4. Can existing barriers be overcome by testing  
   modifications to existing instruments? 
Here, we report the proceedings of the GRAPPA composites workshop at the 2019 
GRAPPA annual meeting and the membership’s recommendations for next steps. 
Patient Research Partner (PRP) Briefing 
Background information on continuous composite measures was developed in lay 
terms for the GRAPPA PRP members and given to PRPs prior to the 2019 GRAPPA 
annual meeting.  
Workshop 
A 2-hour composite measures workshop was held. The workshop opened with an 
introductory session that covered the aims, objectives, background, and relevant 
data of the composite measures field. A question and answer session was then held, 
followed by a 45-minute breakout session that included ten breakout groups to discuss and gain 
an in-depth understanding of the GRAPPA membership’s views on continuous 
composite measures for routine care, challenges to wider adoption of composite 
measures, and next steps. Each group was led by an expert in the field who was 
identified from the GRAPPA-Outcome Measures in Rheumatology (OMERACT) 
working group.(5) The groups were asked to discuss the topic in 2 stages. During the 
first stage, all groups discussed: 
 1. Is there a need for a continuous composite measure of disease activity  
  in PsA? 
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 2. Should modified versions of existing composite measures be  
   tested?  
3. Should shortened versions of existing composite measures be  
  tested?  
4. Is it desirable to measure impact (PSAID) separately from  
activity?  
During the second stage, individual groups were asked to discuss a specific 
composite (3 groups discussed the Disease Activity Index for PsA (DAPSA), 3 
discussed the PsA Disease Activity Score (PASDAS), and 4 discussed the 
Composite Psoriatic Disease Activity Index (CPDAI)): 
 1. Is it feasible?  
2. What modifications could be tested?  
3. What options to shorten could be tested?  
Each breakout group had PRP, rheumatology, dermatology, and industry 
representatives. The breakout group leaders provided key verbal feedback to the 
whole membership in the plenary and a written summary for this report. Voting then 
took place for the attending membership. Additional voting questions were added to 
address questions that arose from the breakout groups and plenary discussions.  
Plenary Presentations 
The need for a continuous composite measure of disease activity. Dr. William Tillett 
opened the plenary presentations with a review of the need for a continuous 
composite measure for routine clinical use in PsA, how the PsAID measure 
influences the debate, the historic lack of patient involvement, and the development 
of a dataset to test modifications to existing candidate measures.  
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It is well known that PsA is a heterogeneous disease that may affect an 
individual in multiple ways, including joints, skin, entheses, spine, systemic feelings 
of fatigue, and associated comorbidities. It is equally recognised that PsA is 
generally not as destructive as RA, but has similar impacts on physical 
functioning, ability to work, and health-related quality of life due to its multiple 
manifestations. Thus, there is a need for a composite measure to better 
quantify wider manifestations of disease activity that would otherwise be 
underrepresented if clinicians and payers only take into account peripheral 
articular disease.  
The pitfalls of current composite measures in PsA. Dr. Tillett highlighted a systematic 
literature review that identified very little patient involvement in the development of 
PsA outcome measures, including composites.(6) The lack of patient involvement, 
and therefore the “lived experience” of PsA, may result in the omission of domains of 
disease that are important to patients, which limits the face validity of existing 
composites.(6) Other challenges to wider adoption of composites include the time-
consuming nature of multiple assessments, complex calculations, 
proprietary/expensive measures, and philosophical concerns related to combining 
outcomes into a single measure.  
Addressing patient involvement. Dr. Tillett reviewed the following program of work 
that addresses the lack of patient involvement in the development of composite 
measures and the ASSESS study that tests modifications as part of the United 
Kingdom (UK) PROMPT programme (early detection to imPRove OutcoMe in people 
with undiagnosed Psoriatic arthriTis) (RP-PG-1212-20007).  
A qualitative study was undertaken to identify outcomes that are 
important to patients. Eight focus groups at 5 hospitals across the UK, 
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including 41 patients, with a range of disease phenotype, disease duration, age, and 
gender, were analysed using thematic analysis.(7) Over 60 outcomes were identified 
and grouped into 4 themes: alleviation of symptoms, reduction of disease impact, 
improved prognosis, and minimisation of treatment harm.(7) The outcomes were 
then ranked using a nominal group technique and mapped to existing composite 
measures, the OMERACT core domain set, and the PsAID questionnaire. Pain and 
fatigue were identified as the outcomes that were most important to patients that 
were not well represented in existing composite measures.(8)  
A conceptual framework for measuring disease impact and disease activity. Dr. 
Tillett then reviewed the concept of disease impact and how the development and 
rapid adoption of the PSAID instrument has influenced the field of composite 
measures of disease activity.  
The concept of disease impact is defined by Sanderson, et al. as a 
culmination of disease severity, self-management, and importance.(9) The PsAID 
instrument has been developed as a PsA-specific measure of disease impact that 
OMERACT has validated and endorsed as a measure of health-related quality of 
life.(10-12) Dr. Tillett presented a conceptual framework for the modification of 
composite measures of disease activity that proposed whether it was theoretically 
desirable for an activity measure to be responsive and not influenced by irreversible 
damage or external factors that are part of measuring impact (such as self-
management and importance to the individual).(13)  
A new dataset to test modification of existing composite measures. Dr. Tillett 
concluded with a review of the ASSESS study undertaken to provide a dataset to 
test modifications to composite measures. Study participants included 141 people 
with PsA who fulfilled the ClASsification for PsA (CASPAR) criteria who were 
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recruited from 5 centres across the UK and assessed at baseline, 3 months and 6 
months, with a wide range of clinical and patient-reported measures to allow for the 
calculation of composite measures. Thirty patients with stable disease were re-
assessed after 1 week. Participants were divided into those who required treatment 
change (as a surrogate for active disease) and those with stable disease (as a 
surrogate for inactive disease). The presence of comorbid fibromyalgia was recorded 
for planned secondary analyses. The composite measures that can be derived from 
the ASSESS study were presented to GRAPPA members, together with their 
potential modifications. 
CPDAI. Professor FitzGerald reviewed the CPDAI.(14) The CPDAI was originally 
conceived to capture the first OMERACT core set and includes assessment of 
peripheral arthritis (66/68 swollen and tender joint count and Health Assessment 
Questionnaire (HAQ)), skin psoriasis (Psoriasis Area Severity Index (PASI) and 
Dermatology Life Quality Index (DLQI), enthesitis (Leeds Enthesitis Score (LEI) and 
HAQ), dactylitis (tender dactylitis count and HAQ), and axial disease (Bath 
Ankylosing Spondylitis Disease Activity Index (BASDAI) and Ankylosing Spondylitis 
Quality of Life Index (ASQoL)). Each domain is scored as 0 (none), 1 (mild), 2 
(moderate), or 3 (severe).(14) The resulting total score ranges from 0 (no disease) to 
15 (active disease). The CPDAI has been validated in randomized controlled trial 
(RCT) datasets and distinguishes active treatment from placebo.(15) CPDAI has 
disease activity cut offs for high, moderate, low disease activity and remission and 
has been shown consistently to be more sensitive to change than DAPSA but not as 
good as PASDAS.(3)  
Professor FitzGerald reviewed why there has not been wider adoption 
of the CPDAI to date. Reasons may include (1) the absence of direct 
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representation of outcomes important to patients (pain and fatigue); (2) the use of 
quality of life measures that are proprietary (ASQoL); (3) the use of HAQ that could 
represent damage/impact rather than activity; (4) the inclusion of the PASI to 
measure skin disease, which is time-consuming for clinicians; and (5) the use of the 
BASDAI as a measure of spinal disease, as BASDAI may reflect peripheral joint 
disease in patients with PsA.  
Professor FitzGerald reviewed previous modifications of the CPDAI and noted 
that as a “modular” measure, the CPDAI is amenable to being adapted. The most 
frequent modification is the omission of the spinal domain, which results in a score of 
0-12. Testing the addition of patient global and pain in the GRAppa Composite 
Exercise (GRACE) dataset did not improve the ability of the CPDAI to detect need 
for treatment change (authors own data, unpublished), but their inclusion may 
improve face validity. Other potential modifications could include (1) the addition of a 
patient-reported outcome measure (PROM) domain that includes patient global, 
fatigue, or pain visual analogue scale (VAS); (2) the use of a short version for 
feasibility; (3) the substitution of the quality of life measures with the PSAID; (4) the 
substitution of PASI with VAS scores/body surface area (BSA); and (5) the use of 
DAPSA as the measure of peripheral articular disease within the CPDAI. All such 
modifications could be tested in data obtained in the ASSESS study. 
PASDAS. Dr. Helliwell presented a review of the PASDAS, an 8 item score 
comprised of (1) 66 swollen joint count, (2)68 tender joint counts, (3) tender dactylitis 
count, (4) physician global VAS, (5) patient global VAS, (6) C-reactive protein (CRP), 
(7) Leeds Enthesitis Index, and (8) physical function component of the SF-36 or SF-
12.(16) The PASDAS score ranges between 0 (no disease) and 10 (severe disease) 
based on a weighted formula and has validated cut offs for high, moderate, and low 
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disease activity, and near remission. As opposed to the CPDAI, which was 
developed to be comprehensive and cover all clinical domains of disease, the 
PASDAS was developed as a composite measure of disease activity using a data-
driven approach, including only outcomes that improve ability to detect change. The 
PASDAS has been shown to perform better than purely articular measures in 
multiple datasets and predicts radiographic progression.(15, 17) Dr. Helliwell 
reviewed what is desirable from a composite measure of disease activity (for routine 
care) perspective, including the need to be feasible, meaningful, and responsive, as 
well as the need to capture all disease manifestations. When considering why the 
PASDAS has not been adopted more widely, he explained that the measure is 
perceived to be complicated, time-consuming (as it requires multiple clinical 
assessments and a laboratory test), and difficult to calculate. Modifications to the 
PASDAS could be tested, including the addition of pain, fatigue, or different 
measures of physical function. A self-assessment PASDAS is currently under 
evaluation and is focused on arthritis, enthesitis, dactylitis, and psoriasis skin VAS 
scores.  
DAPSA. Dr. Tillett reviewed the DAPSA instrument, which is comprised of the 66/68 
swollen and tender joint count, joint pain VAS, patient global VAS, and CRP.(18) The 
clinical DAPSA (cDAPSA), which does not include CRP, is also available for use in 
order to improve feasibility. The DAPSA has been validated in RCT datasets, has 
established cut points for remission (≤4), as well as low (>4 and ≤14), moderate (>14 
and ≤28), and high disease activity states (>28).(19) The DAPSA correlates well with 
physical function and structural damage in RCT datasets.(20) The DAPSA is a 
measure of peripheral joint disease in PsA rather than a comprehensive measure of 
disease, as it does not include measures of enthesitis, psoriasis, dactylitis, or axial 
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disease. The DAPSA also does not include measures of physical function, quality of 
life, or fatigue. Potential modifications should be approached with caution as the 
strength of the DAPSA lies in its feasibility and its focus on 1 aspect of disease, joint 
manifestations. Potential modifications to DAPSA could include additional 
musculoskeletal manifestations (enthesitis, dactylitis, axial disease), skin disease, or 
testing the DAPSA as a subcomponent of the CPDAI.  
Breakout Group Summary  
The GRAPPA composites workshop participants were divided into 10 breakout 
groups. The results of the groups discussing the CPDAI, PASDAS, and DAPSA are 
detailed in Table 1, Table 2, and Table 3, respectively. The composition of GRAPPA 
members who participated in the plenary voting, as well as the plenary voting results 
are reported in Table 4. 
Is there a need for a continuous composite measure of disease activity in PsA?  
The majority of members agreed that there is a need for a continuous composite 
measure for routine practice (88.8%), but nearly two thirds of the voting membership 
(65%) were either using the DAS28 (26.8%) or no measure at all (38%). Only a 
minority were using a PsA-specific measure such as the DAPSA (12.7%), PASDAS 
(5.2%), and CPDAI (3%). The remainder (14.2%) were using other measures. All 10 
breakout groups agreed that a composite measure of disease activity was needed 
for routine clinical practice; consensus on a single measure was desirable; impact 
and activity should be measured separately  
Should modified versions of existing composite measures be tested? The majority of 
members supported the testing of modifications to both the CPDAI (71.6%) and the 
PASDAS (81.8%) to address barriers to wider adoption (Table 4). Opinions were 
split on the testing of modifications to the DAPSA with 52% voting to leave the 
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DAPSA unchanged and 48% voting to test modifications (Table 4). There was a 
minority view expressed that, instead of modifying existing composite measures, a 
new measure should be developed based on the updated 2016 core domain set with 
an improved conceptual framework. It was suggested that the 3 Visual Analogue 
Scale (3VAS) score and Routine Assessment of Patient Index Data 3 (RAPID3) 
should be considered as other options for a continuous composite measure of 
disease activity. The 3VAS and RAPID3 were not included in this present workshop 
because of discussions at a previous international consensus meeting where there 
have been reservations about taking forward measures that do not include physical 
examination/clinical assessment.(3) It was suggested that either the 3VAS or 
RAPID3 could be tested as a short version of a more comprehensive composite. 
Should shortened versions of an existing composite measure be tested? Members 
felt the existing measures, CPDAI (84%), PASDAS (82%), and DAPSA (47%), were 
not feasible in their current forms. Members agreed that modifications and 
shortenings should be tested (Table 4), with most supporting the testing of more 
prominent inclusion of pain and more feasible methods of psoriasis assessment. 
There were no strong differences between dermatologist and rheumatologist voting, 
with the exception of the PASI. As a group, 79% voted that the PASI was not 
feasible in routine practice. A breakdown of those voting on the PASI indicated that 6 
of 18 (33%) dermatologists voted the PASI to be feasible, but only 15 of 86 (17%) 
rheumatologists voted the PASI to be feasible. The challenge of performing the 66/ 
68 joint count in clinical practice was raised in a DAPSA breakout group and 
discussed in the plenary during feedback. It was recognized that the 66/68 joint 
count was necessary to adequately assess joint disease and the challenge of 
feasibility related to the joint count applied to the CPDAI, PASDAS, and DAPSA. 
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Another limitation of the DAPSA discussed in the breakout group was the 
requirement for a CRP to complete the DAPSA (not required in the cDAPSA) as the 
CRP is frequently not available at the time of the visit.  However, this differed by 
country and by practice. There was debate in each group about striking the balance 
between shortening a composite measure to make it feasible in clinical practice 
versus oversimplifying a measure that then fails to achieve its purpose of being a 
more global assessment of disease.  
Is it desirable to measure impact (PSAID) separately from activity? There was strong 
agreement (76%) that impact should be measured separately from activity in the 
voting, and the same message was communicated in the breakout groups’ feedback.  
Summary 
In this meeting report from the 2019 GRAPPA composites workshop, we detail the 
rationale for a continuous composite measure of disease activity for routine care in 
PsA and the challenges to wider adoption. We detail the barriers to uptake of the 
CPDAI, PASDAS, and DAPSA, as well as the GRAPPA membership’s views on how 
to take each measure forward, specifically disadvantages of each measure and 
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Table 1. Summary of Composite Psoriatic Disease Activity Index (CPDAI) Group 
Discussions. 
Key views of 4 CPDAI groups (composed of 6 PRPs, 38 rheumatologists, 6 
dermatologists, 2 academics, and 6 members of industry) 
 Themes independently arising in all 4 groups with general agreement 
 • CPDAI is not feasible for routine practice in its current form  
 • Skin domain is important and should be included 
 • PASI is not feasible in routine practice 
 • More feasible skin measure should be tested (VAS/BSA/BSA x 
PGA) 
 • Short version of CPDAI should be tested 
 • Improved representation of PROMS should be tested  
 • Recognized that PROMS also need administrative support to 
deliver (electronic/printing/calculation) 
 • Axial domain important 
 • BASDAI influenced by peripheral disease 
 • Spinal VAS/Likert could be tested 
 • Physical function important but potentially influenced by 
damage 
 • Impact (using PSAID) should be assessed separate from 
activity 
 Additional comments arising in individual groups without 
agreement 
 • Consider testing PSAID substitution for 
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ASQoL/HAQ/BASDAI/DLQI 
 Debate in 1 group about advantages of including physical function 
with HAQ versus disadvantages of including a measure of damage in 
an activity measure, has floor effect. 
 • Global VAS may also be influenced by impact/damage 
 •  
 
CPDAI: Composite Psoriatic Disease Activity Index; PRPs: Patient Research 
Partners; PASI: Psoriasis Area Severity Index; VAS: visual analogue scale; BSA: 
body surface area; PGA: physician’s global assessment; PROMs: patient-reported 
outcome measures; BASDAI: Bath Ankylosing Spondylitis Disease Activity Index; 
HAQ: Health Assessment Questionnaire; DAPSA: Disease Activity for PsA; PSAID: 
PsA Impact of Disease; ASQoL: Ankylosing Spondylitis Quality of Life Index; DLQI: 
Dermatology Life Quality Index. 
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Table 2. Summary of PsA Disease Activity Score (PASDAS) Group Discussions. 
Key views of 3 PASDAS groups (composed of 4 PRPs, 32 rheumatologists, 4 
dermatologists, 1 academic, and 4 members of industry) 
 Themes independently arising in all 3 groups with general agreement 
 • PASDAS not feasible clinically in its current form 
 • Modifications should be tested 
 • Skin domain important and should be tested in PASDAS or 
measured separately 
 • SF-36 is not feasible in routine practice; test substitutions 
 • Physical function important but potentially influenced by 
damage 
 • Impact (using PSAID) should be assessed separate from 
activity 
 Additional comments arising in individual groups without agreement 
 • Need for a calculation (formula) is a disadvantage 
 • Consider reviewing CRP (2 groups) and dactylitis (feasibility) 
 • Nails, axial disease, fatigue, and pain are missing components 
 • Debate over oversimplifying (shortening) a composite thereby 
failing its objective of assessing the total burden of disease 
versus making feasible for practice. Given the lack of 
agreement, should a new composite be created? 
 • 2 people in 1 group voiced concern that combining outcomes 
“dilutes” individual domains. This is a strength of the DAPSA 
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PSA: psoriatic arthritis; PASDAS: PsA Disease Activity Score; PRPs: Patient 
Research Partners; SF36: Short Form-36; VAS: visual analogue scale; HAQ: Health 
Assessment Questionnaire; DAPSA: Disease Activity for PsA; PSAID: PsA Impact of 
Disease; CRP: C-reactive protein.  
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Table 3. Summary of Disease Activity for PsA (DAPSA) Group Discussions. 
Key views of 3 DAPSA groups (composed of 3 PRPs, 33 rheumatologists, 3 
dermatologists, 0 academics, and 3 members of industry) 
 Themes independently arising in all 3 groups with general agreement 
 • DAPSA is a measure of peripheral articular disease in PsA  
 • A strength of DAPSA is the separate measurement of peripheral 
arthritis, therefore not diluted/influenced by other domains 
 • DAPSA is not a measure of psoriatic disease or the total burden 
of PsA 
 • cDAPSA is feasible clinically in its current form 
 • Modifications could be tested, including a skin module and 
additional MSK manifestations (enthesitis) 
 • DAPSA could be tested as a “module” to assess peripheral 
articular disease in CPDAI  
 • Impact (using PSAID) should be assessed separate from activity 
 Additional comments arising in individual groups without agreement 
 • Could DAPSA be used for screening in dermatology clinics? 
 • CRP was felt to be a significant limitation for feasible integration 
into clinical practice in some countries, including the United 
States, where CRP is often not available at the time of the visit. 
 • 66/68 joint count is challenging in clinical practice (applies to 
PASDAS and CPDAI, as well) 
 • DAPSA responses in RCTs not as good as other composites 
  The continuous score is useful for clinical practice 
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  Practicing non-academic clinicians do not use PROs 
  3 VAS score or RAPID3 is feasible and should be 
considered 
  Fibromyalgia impacts all PROs 
  PROs help promote self-efficacy 
  Rheumatologists struggle to assess skin 
 
PSA: psoriatic arthritis; DAPSA: Disease Activity for PsA; PRPs: Patient Research 
Partners; cDAPSA: clinical DAPSA; MSK: musculoskeletal; CPDAI: Composite 
Psoriatic Disease Activity Index; PSAID: PsA Impact of Disease; PASDAS: PsA 
Disease Activity Score; RCTs: randomized controlled trials; PROs: patient-reported 
outcomes; VAS: visual analogue scale; RAPID3: Routine Assessment of Patient 
Index Data 3.  
  
20 December 2019    Page 22 of 27 
 
Table 4. Plenary Voting Questions and Results. 




No 17 (11.8%) 
Total 
Total 152 
2. Impact (all the ways an individual is affected by PsA: severity/self-management and 








3. For people with PsA, which continuous composite activity measure (if any) do you 
use in routine clinical practice (select any you use)? 















4. Is CPDAI feasible in its current form? 






5. Is PASI feasible in routine practice?  






6. Should modifications of CPDAI be tested? 






• If “Yes” to “Should modifications of CPDAI be tested”, please select any of the 
following you recommend testing: 
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 • Addition of Pain/fatigue/Patient Global): 59 (23.0%) 
 • More feasible skin measure (BSA versus PASI), BSA: 83 (32.3%) 
 • Alternative spinal measures: 48 (18.7%) 
 • Should DAPSA be tested as an articular module: 24 (9.3%) 
7. Should shortenings of CPDAI be tested? 






8. Is PASDAS feasible in its current form? 






9. Should modifications of PASDAS be tested? 






• If “Yes” to “Should modifications of PASDAS be tested”, please select any you 
recommend testing: 
 •  Pain VAS: 63 (29%)  
 •  Fatigue: 61 (28%) 
 •  Skin: 94 (43%)  
10. Should shortenings of PASDAS be tested (such as PROM only)? 






11. Is DAPSA feasible in its current form? 
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12. Is cDAPSA feasible in its current form? 






13. Is DAPSA a measure of peripheral PsA or peripheral psoriatic disease? 
 •  Peripheral PsA: 98 (86.7%) 
 •  Peripheral psoriatic disease: 63 (13.3%) 
 •  Total: 113 
14. Should DAPSA be left in its current form? 






•  If “No” to “Should DAPSA be left in its current form”, should other domains be 
tested (enthesitis/axial disease)? 
 •  MSK (i.e., enthesitis): 17 (20%)  
 •  Axial disease: 13 (15.3%)  
 •  Skin: 55 (64.7%)  
 
PSA: psoriatic arthritis; PSAID: PsA Impact of Disease; DAS28: Disease Activity 
Score-28; DAPSA: Disease Activity for PsA; PASDAS: PsA Disease Activity Score; 
CPDAI: Composite Psoriatic Disease Activity Index; PASI: Psoriasis Area and 
Severity Index; DAPSA: Disease Activity Index for PsA; BSA: body surface area; 
VAS: visual analogue scale; PROM: patient-reported outcome measures; cDAPSA: 
clinical DAPSA; MSK: musculoskeletal.  
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